Trial Profile
Phase I/II Trial of Anti-IGF-IR Monoclonal Antibody IMC-A12 Plus mTOR Inhibitor Temsirolimus (CCI-779) in Metastatic Castration- Resistant Prostate Cancer (CRPC)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Cixutumumab (Primary) ; Temsirolimus (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 25 Aug 2015 Planned primary completion date changed from 1 Sep 2015 to 1 Sep 2016 as reported by ClinicalTrials.gov
- 21 Oct 2014 According to ClinicalTrial.gov record, planned End Date changed from 1 Jun 2014 to 1 Sep 2015.
- 21 Oct 2014 According to ClinicalTrial.gov record, planned primary completion date changed from 1 Jun 2014 to 1 Sep 2015.